secwatch / observer

8-K filed April 25, 2023, 7:59 PM ET ticker FNCHQ CIK 0001733257

leadership confidence high sentiment neutral materiality 0.70

Finch Therapeutics replaces CEO and CFO; Blischak appointed CEO effective May 16

Finch Therapeutics Group, Inc.

CEO Mark Smith and COO Marc Blaustein terminated without cause, effective May 15, 2023; Smith resigns from board.
Matthew P. Blischak named CEO effective May 16; base salary $400k, target bonus 40%, option grant of 962,899 shares.
Lance Thibault (Danforth Advisors) named CFO effective May 16; paid hourly $525.
Former executives to remain as consultants under advisory agreements.
Company emphasizes foundational IP estate (over 70 issued patents) as key asset.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew P. Blischak

Chief Executive Officer

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2023-05-16
Filed: April 25, 2023, 7:59 PM ET

Additionally, on April 21, 2023, and effective as of May 16, 2023, the Board appointed Matthew P. Blischak to serve as the Company’s Chief Executive Officer

Departed

Marc Blaustein

Chief Operating Officer

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2023-05-15
Filed: April 25, 2023, 7:59 PM ET

On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.

Departed

Mark Smith

Director

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2023-05-15
Filed: April 25, 2023, 7:59 PM ET

Further, on April 21, 2023, Dr. Smith resigned as a member of the Board, effective as of May 15, 2023.

Appointed

Lance Thibault

Chief Financial Officer

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2023-05-16
Filed: April 25, 2023, 7:59 PM ET

and Lance Thibault to serve as the Company’s Chief Financial Officer.

Departed

Mark Smith

Chief Executive Officer

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2023-05-15
Successor: Matthew P. Blischak
Filed: April 25, 2023, 7:59 PM ET

On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew P. Blischak was appointed as Chief Executive Officer at Finch Therapeutics Group, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Additionally, on April 21, 2023, and effective as of May 16, 2023, the Board appointed Matthew P. Blischak to serve as the Company’s Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Blaustein was terminated as Chief Operating Officer at Finch Therapeutics Group, Inc..

Action: terminated
Role: Chief Operating Officer

Exact text from the filing

On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Smith resigned as Director at Finch Therapeutics Group, Inc..

Action: resigned
Role: Director

Exact text from the filing

Further, on April 21, 2023, Dr. Smith resigned as a member of the Board, effective as of May 15, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lance Thibault was appointed as Chief Financial Officer at Finch Therapeutics Group, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

and Lance Thibault to serve as the Company’s Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Smith was terminated as Chief Executive Officer at Finch Therapeutics Group, Inc..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.

View on SEC.gov

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-014424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.